Praktické lekárnictvo 3/2017

New classification of venoactive drugs

Chronic venous disease (CVD) represents a major health problem, as its prevalence is high – up to 84% of population including patients with clinical stage C0 (Vein Consult Programme, 2012). Venoactive drugs (VAD) are a basic conservative treatment of CVD. New guidelines for the treatment of CVD were published in 2014. There are changes in classification of VAD based on their safety and efficacy. Micronized purified flavonoid fraction (MPFF) is now the only VAD with grade 1B (a strong recommendation based on moderate evidence). Rutosides, red wine leaves extracts, calcium dobesilate, horse chestnut seed extract and Ruscus extract are all given grade 2B (weak recommendations based on moderate evidence). Nonmicronized diosmins and Gingko biloba are given grade 2C (weak recommendations based on low quality evidence). MPFF is indicated in all stages of CVD and it is the only VAD recommendated in the treatment of venous leg ulcers.

Keywords: chronic venous disease, venoactive drugs, classification, micronized purified flavonoid fraction